Furthermore, veliparib treatment (another type of PARPi) of PTEN-null PC3-AR prostate cancer mouse xenografts has been shown to enhance RAD51 expression and HR activity under hypoxic conditions and reduce chemotherapy-mediated DNA damage and cell apoptosis [86]. Here, PTEN is linked to prostate carcinoma.